Wasatch Biolabs provides advanced native-read sequencing services utilizing Oxford Nanopore technology for genomic and epigenomic analysis. The company specializes in proprietary platforms like Direct Whole Methylome Sequencing (dWMS) to deliver high-resolution methylation and variant profiling without bisulfite conversion. These scalable solutions support applications ranging from early biomarker discovery to clinical-ready precision diagnostics.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current DNA methylation analysis methods rely on bisulfite conversion, which can introduce biases and artifacts, leading to inaccurate results, especially when working with limited or degraded samples. Traditional methods also often require amplification, further compounding these issues and hindering the discovery of true epigenetic biomarkers.
Solution
Wasatch BioLabs offers Next-Generation Sequencing (NESSI-Seq), a native-read sequencing platform that eliminates the need for bisulfite conversion and amplification in DNA methylation analysis. By directly sequencing native DNA, NESSI-Seq minimizes biases and batch effects, providing more accurate and sensitive results. The platform is optimized for challenging samples, such as cell-free DNA (cfDNA), and delivers precise enrichment for specific genomic regions. This technology enhances genetic and epigenetic biomarker discovery and enables high-throughput, targeted sequencing applications.
Target Audience
The primary customers are biopharmaceutical companies, clinical service providers, and academic research institutions seeking accurate and scalable DNA methylation analysis for biomarker discovery and clinical diagnostics.
Features
- Native DNA sequencing that bypasses bisulfite conversion and PCR amplification
- High-sensitivity assays optimized for challenging samples like cfDNA
- Targeted accuracy for precise enrichment of specific genomic regions
- CLIA-accredited laboratory certified for high-throughput clinical processing
- Automated workflows for efficient and scalable data analysis
- Custom assay development leveraging the NESSI-Seq platform
- Direct Whole Methylome Sequencing
- Bisulfite-Free Targeted Methylation
- Cell-Free Whole Genome Methylation Sequencing